PDCD1 and neoplasm: In order to optimize the antitumor efficacy of PD-1/PD-L1 antibodies, we developed the first novel anti-TGF-β/VEGF bispecific antibody Y332D, which can simultaneously block both immune-negative signals TGF-β and VEGF in the tumor microenvironment.